Clinical Development, Hormones and Protein - Clinical Research Informer

Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). It is developed based on sympress platform technology. It is administered as an intravenous infusion.

Generic Drugs

Generic Drugs Hormones Manufacturing Development

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. (Nasdaq: ARVN) and Pfizer Inc.

Protein

Protein Development HR Hormones

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development

Development Hormones Drugs Trials

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) together With Chemotherapy surely Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative carcinoma Whose Tumors Express PD-L1 (CPS ?10)

The Pharma Data

SEPTEMBER 28, 2021

Merck is rapidly advancing a broad portfolio in gynecologic and breast cancers through an in depth clinical development program for KEYTRUDA and a number of other other investigational and approved medicines across these areas. About Triple-Negative carcinoma.

Hormones

Hormones Medicine Clinical Research Research

A Complex Chromosomal Abberation Called Adrenoleukodystrophy

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.

Hormones

Hormones Marketing Gene Trials

Three trends in the antibody-drug conjugate (ADC) market

Drug Discovery World

JUNE 1, 2023

BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumour effects on breast, lung and other solid tumors that express HER2.

Antibody

Antibody Marketing Drugs Licensing

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation.

HR

HR Medicine Hormones Trials

Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

The Pharma Data

AUGUST 30, 2021

KEYTRUDA Now Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer. KEYTRUDA Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer.

Hormones

Hormones HR Trials Protein

Where are the advances in treatments for triple-negative breast cancer?

Drug Discovery World

AUGUST 21, 2023

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. However, because these cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs, current treatment options are limited.

Protein

Protein Trials Clinical Trials Clinical Trials

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR

HR Medicine In-Vitro Development

Could an Antibody Drug Help You Shed Pounds?

The Pharma Data

NOVEMBER 2, 2020

That’s one finding from an early study that tested the injection drug, which mimics the effects of a natural hormone called fibroblast growth factor 21 (FGF21). FGF21 is a hormone that helps control metabolism by stimulating certain receptors in fat tissue, the liver, the pancreas and the central nervous system. MONDAY, Nov.

Antibody

Antibody Drugs Hormones Insulin

Ascendis Pharma A/S Provides Vision 3×3 Update at 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

JANUARY 10, 2021

By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?. . . . . ?.

Hormones

Hormones Clinical Development Clinical Trials Clinical Trials

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales

Sales Manufacturing FDA Approval Life Science

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher.

Clinical Trials

Clinical Trials Clinical Trials Trials Clinical Development

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

The Pharma Data

MARCH 17, 2021

In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4 & 6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. Across the clinical development program, deaths due to venous thromboembolism have been reported.

HR

HR Trials In-Vitro Manufacturing

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Immune-Mediated Pneumonitis.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Immune-Mediated Pneumonitis.

Trials

Trials Hormones Clinical Trials Clinical Trials

BioSpace Global Roundup, Oct. 15

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. CARB-X will provide Polyphor with initial funding of up to $2.62

Clinical Trials

Clinical Trials Clinical Trials Manufacturing Trials

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

The Pharma Data

DECEMBER 27, 2020

Proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or no longer needed. i KYPROLIS has been shown to block proteasomes, leading to an excessive build-up of proteins within cells. Since its first approval in 2012, approximately 150,000 patients worldwide have received KYPROLIS.

Production

Production Drugs Clinical Trials Clinical Trials

Clinical Research Informer

Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

Trending Sources

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) together With Chemotherapy surely Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative carcinoma Whose Tumors Express PD-L1 (CPS ?10)

A Complex Chromosomal Abberation Called Adrenoleukodystrophy

Three trends in the antibody-drug conjugate (ADC) market

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

Where are the advances in treatments for triple-negative breast cancer?

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

Could an Antibody Drug Help You Shed Pounds?

Ascendis Pharma A/S Provides Vision 3×3 Update at 39th Annual J.P. Morgan Healthcare Conference

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

BioSpace Global Roundup, Oct. 15

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

Stay Connected